Bringing innovative therapies to patients with unmet medical needs

Finn Therapeutics as a driver to move novel “first-in-class” biologic candidates

Heading

This is some text inside of a div block.

Bringing innovative therapies to patients with unmet medical needs

Finn Therapeutics as a driver to move novel “first-in-class” biologic candidates

Providing support to advocate and empower patients

Changing the paradigm in Oncology

Bringing innovative therapies to patients with unmet medical needs

Changing the paradigm in Oncology

Leveraging the power of translational research to create truly personalized medicines

Changing the paradigm in Oncology

Driving cutting-edge candidates to the bedside

Changing the paradigm in Oncology

Our Company

...capitalizes on the latest biology breakthroughs to innovate and develop the next generation of cancer therapy that directly targets the tumor microenvironment and tumor metastasis.…  

founded by oncologists, scientists and an experienced management team that has built numerous successful life sciences ventures.

Our Team

Finn Tx's scientists bring more than 20 years of experience in drug development in oncology. Our team consists of scientists and advisors with extensive experience in cancer biology, monoclonal antibodies discovery and engineering, IND-enabling studies and clinical studies.


FinnTx is located in Belfast, an UK-leading hub of biotech and pharmaceutical industry.

Julie Gormley
Ph.D., Operating Office

20 years of experience in pharma business development

Mohamed Bekradda
M.D., Medical Oncologist

25 years of experience as clinical development leader for Phase I and II trials

Eugenia Riveiro
Ph.D., Scientific Officer

15 years of experience in preclinical development

Paul Kerr
Ph.D., Director

Former CEO for 20 years of an antibody development CRO in Belfast - a company on LSE in 2017 with 60 employees

Christophe Mazars
MBA Chief Executive Office

20 years of experience in CRO organizations in oncology development as CFO

Keyvan Rezai
Ph.D., Clinical Pharmacologist

25 years of experience in PK/PD studies and modelling

L’Houcine Ouafik
Ph.D.

International KOL in Adromedullin signaling in oncology

Kay Noel
Ph.D.

Over 30 years experience in pharmaceutical development with 10 NDA approvals

Updated on
24/1/2022

Our pipeline

Focusing on Cancers with High Unmet Medical Needs

We are focused on the discovery of novel antibodies for diseases with high unmet medical needs - leveraging our platform technology and core competencies

TARGETING THE TUMOR MICROENVIRONMENT TO FIGHT CANCER

Our First-in-class/First-in-man approach is a feasible strategy for the treatment of hypoxic tumors, VEGF- acquired resistant tumors and metastasis development

Program
FT-12
Clinical Indications
Breast ER+ Prostate
Preclinical

Stage Complete
IND-Studies

Stage Complete
Phase I

Stage Complete
Program
FT-09
Clinical Indications
Pancreatic Hepatocarcinoma Renal cell Carcinoma
Preclinical

85

Stage Complete
IND-Studies

Stage Complete
Phase I

Stage Complete

CLINICAL DEVELOPMENT STRATEGY: FOCUS ON NICHE TUMORS OR NARROWER STRATIFICATION OF SUBPOPULATIONS IN MORE COMMON TUMOR TYPES.

Latest Events & Press Releases

BioTrinity 2022

Don’t miss the opportunity to meet our team. We look forward to seeing you in London.

Posted on:
February 3, 2022

AACR Annual Meeting 2022

Don’t miss the opportunity to meet our team. We look forward to seeing you in New Orleans, US.

Posted on:
February 3, 2022

DOWNLOAD SUMMARY PDF

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

DOWNLOAD PDF

Endorsed by